Motley Fool  Aug 31  Comment 
Management had a lot of information to share with investors when it reported second quarter earnings. Here are 5 key takeaways.
Forbes  Aug 26  Comment 
I like the drug Afrezza, I am not a MannKind bull and I don’t much like how the company is being run. Maybe that will change when/if Afrezza sales pick up, but predicting that is beyond my area of expertise.
TheStreet.com  Aug 20  Comment 
Correction: MannKind converted $8 million of debt into 1.9 million shares of company stock. A typing error in the original version of the story said the conversion was 9 million shares. The story has been corrected.  VALENCIA, Calif....
Forbes  Aug 19  Comment 
I really don’t like dumping on MannKind nor do I take any great pleasure in watching shares slide. Yet it is fun to read the things MannKind supporters write, how they explain in spite of those pesky facts that MannKind shares are a bargain.
TheStreet.com  Aug 10  Comment 
NEW YORK (TheStreet) -- MannKind  shares are gaining 0.25% to $4.04 in after-hours trading on Monday after the company reported its fiscal 2015 second quarter earnings results before the opening bell today that beat analysts' estimates. ...
Benzinga  Aug 10  Comment 
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. MannKind Corporation (NASDAQ: MNKD) shares were trading higher by $0.17 at $4.15 in Monday's session. Before the open, the company announced a Q2 loss...
SeekingAlpha  Aug 10  Comment 
SeekingAlpha  Aug 10  Comment 
FiercePharma  Aug 3  Comment 
There's been lots of hullaballoo surrounding Sanofi and MannKind's launch of inhaled insulin Afrezza, but for the arrival of the pair's first DTC campaign? Not so much.


MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.


MannKind's primary competitors include:


  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki